Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M, Kiepas A, El-Houjeiri L, Annis MG, Hsu BE, Fortier AM, Morin G, Martina JA, Sirois I, Aguilar-Mahecha A, Gruosso T, McGuirk S, Rose AAN, Tokat UM, Johnson RM, Sahin O, Bareke E, St-Pierre J, Park M, Basik M, Majewski J, Puertollano R, Pause A, Huang S, Keler T, Siegel PM. Biondini M, et al. Among authors: keler t. Oncogene. 2022 Mar;41(12):1701-1717. doi: 10.1038/s41388-022-02206-z. Epub 2022 Feb 2. Oncogene. 2022. PMID: 35110681
[89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B-targeted Therapy in Triple-negative Breast Cancer.
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. Lee S, et al. Among authors: keler t. Mol Cancer Ther. 2022 Mar 1;21(3):440-447. doi: 10.1158/1535-7163.MCT-21-0590. Mol Cancer Ther. 2022. PMID: 35027482 Free PMC article.
Antibody-targeted vaccines.
Keler T, He L, Ramakrishna V, Champion B. Keler T, et al. Oncogene. 2007 May 28;26(25):3758-67. doi: 10.1038/sj.onc.1210375. Oncogene. 2007. PMID: 17530028 Review.
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. McGregor BA, et al. Among authors: keler t. Invest New Drugs. 2020 Dec;38(6):1807-1814. doi: 10.1007/s10637-020-00945-y. Epub 2020 May 29. Invest New Drugs. 2020. PMID: 32472319 Free PMC article. Clinical Trial.
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ, Vitale L, O'Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T. Thomas LJ, et al. Among authors: keler t. Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26. Mol Cancer Ther. 2016. PMID: 27671527
115 results